Cancer research moves fast. We make it understandable.
The FDA granted 510(k) clearance -- a real FDA regulatory action for a diagnostic device, distinct from the drug-approval pathway most other records on this site describe -- to Ibex…
Primary source cited
Last reviewed
In the single-arm, open-label, phase 1/2 MonumenTAL-1 trial, talquetamab produced meaningful, durable responses in patients with heavily pretreated, relapsed or refractory multiple myeloma who had already exhausted the major available…
Primary source cited
Last reviewed
In the randomized, phase 3 CodeBreaK 300 trial, sotorasib plus panitumumab significantly extended progression-free survival (5.6 months vs 2.0 months, hazard ratio 0.48) and improved objective response rate (26% vs…
Primary source cited
Last reviewed
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV…
Primary source cited
Last reviewed
In the prospective, 20,176-participant BLUE-C study, Cologuard Plus (a next-generation multitarget stool DNA test) detected colorectal cancer with 95% sensitivity and correctly identified 94% of participants without colorectal cancer or…
Primary source cited
Last reviewed
A peer-reviewed case series describing three patients who self-administered fenbendazole (a veterinary dewormer, not an approved human cancer drug) alongside their standard cancer treatment, and reported remission, was published in…
Primary source cited
Last reviewed
In the randomized, phase 2b KEYNOTE-942 trial, adding a personalized mRNA cancer vaccine (manufactured for each patient's own tumor mutations) to pembrolizumab reduced the risk of melanoma recurrence or death…
Primary source cited
Last reviewed
In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON…
Primary source cited
Last reviewed
In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in…
Primary source cited
Last reviewed
In the single-arm, open-label C-144-01 trial, a one-time infusion of a patient's own expanded tumor-infiltrating lymphocytes (lifileucel) produced an objective response in 31.5% of patients with advanced melanoma who had…
Primary source cited
Last reviewed